Redesigned lung cancer drug matches tumor control with fewer off-target interactions

Researchers at Moffitt Cancer Center have developed a new chemical approach that could help make targeted cancer medicines safer and more precise. The discovery gives scientists a new way to design drugs that bind more selectively to cancer-driving proteins while reducing unwanted interactions that can lead to side effects.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup